Form 4: Relmada Therapeutics Director John Glasspool Acquires and Forfeits Stock Options

Director John Glasspool acquired and then forfeited stock options in Relmada Therapeutics on May 24, 2024, related to the company's 2021 Equity Incentive Plan.

Summary

• On May 24, 2024, John Glasspool, a director of Relmada Therapeutics, acquired options for 20,976 shares of common stock at an exercise price of $2.48 per share.
• These options were granted under the terms of the December 15, 2023 option award, becoming available due to expirations, cancellations, forfeitures, and terminations of other outstanding awards under the company's 2021 Equity Incentive Plan.
• On the same day, Glasspool voluntarily forfeited these 20,976 options so that they could be allocated to holders of similar awards who are not executive officers or directors of the Issuer.
• Following these transactions, Glasspool directly owns 31,522 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock option transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders and their holdings in the company's stock.

Stakeholder Impact

• The forfeiture of options by the director allows for reallocation to other employees, potentially boosting morale and aligning incentives.

Key Dates

Keywords

Relmada Therapeutics, John Glasspool, stock options, Form 4, Equity Incentive Plan, director, RLMD